

Sector Vector Newsletter Promotional Opportunities



Key Metrics

*Average of issues Jan-Dec 2025



18,000+
subscribers



27%
average open rate*




8%
average click rates*




25%+
recipients are executive
leaders

Executive Leadership
(Common titles: CEO, COO, VP)



Audiences



PLACEMENT OPTIONS

▶ Banner Placement – Top

Hyperlinked banner and summary description (25 words or less).

Placement Bundles (subject to availability):



▶ Banner Placement – Middle

Hyperlinked banner

Placement Bundles (subject to availability):



▶ Banner Placement – End

Hyperlinked banner

Placement Bundles (subject to availability):



▶ Job Postings (Maximum 8 weeks)

Member Rate: → **\$150** per job posting per week

Non-Member Rate: → **\$200** per job posting per week

AD PLACEMENTS



THE SECTOR VECTOR
 Delivering the latest news in gene therapy, cell therapy, & tissue engineering
 May 15, 2024
Orphan Drug
 Congress 2024
 REGISTER TODAY!
 Join the **World's Largest Orphan Drug and Rare Disease Events** as we cover the start-to-finish of orphan drugs, from regulation and policy to global pricing and gene therapy...

Business
 Bluebird bio announces first patient's cells collected for LYFGENIA and that 14 patient scans were completed for ZYNTEGLO and SKYSONA since the beginning of 2024 - May 9
 Evance Biotherapeutics Updates That More Than 100 Patients Have Enrolled for Its Anticopy Cell Therapy Since FDA Approval - May 9
 Dymo Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVDSA AI - May 9
 Artor Biotechnologies Announces Acquisition of Serendipity - May 8
 Astellas Unveils New, State-of-the-Art, \$92 Million West Coast Innovation Center in the South San Francisco Biotech Corridor - May 8
 Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT) Announces Agreement to Commercialize TrICAR-T Cell Immunotherapy for Leukemia and Lymphoma - May 7

**Top banner
ad placement**



CELL AND GENE
 Register for your free weekly newsletter

Manufacturing
 Siron Biotechnology and Catalent Emser Partnership for Manufacturing of AAV Gene Therapies for Cancer - May 8
 Donaldson Announces Integrated Lentiviral Vector Manufacturing Platform Development - May 8
 Cellgene Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X08 Platform - May 7
 WACKER Expands Production Capacity for Biopharmaceuticals in San Diego - May 6
 Takara Bio launches first commercial dissolvable microfluidic lentiviral transduction enhancer - May 6

**Middle banner
ad placement**



INCLUSION
 Tackle challenges in diversity, equity, and inclusion with leaders in life sciences.

Clinical & Scientific
 Stormsbury Genetic Therapies Showcases its First Preclinical Data on Parkinson's Disease Program - May 8
 Fresenius Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting - May 9
 Kate Therapeutics Presented Key Advances in Next-Generation DMD Gene Therapy - May 9
 Fosenda Therapeutics Highlights Strong Progress on its Genetic Medicine Programs at the ASGCT 27th Annual Meeting - May 9
 Kite And Arctis Continue Momentum with Advances in Anti-CD4 Multiple Myeloma Program - May 9
 Epitor Therapeutics Unveils CasMeno: A Compact, All-in-One CRISPR/Cas for Single AAV Therapies at the American Society of Gene & Cell Therapy Annual Meeting - May 9
 Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing - May 9

Expedited Approval & Orphan Designations
CDER Grants Orphan Drug Designation - Phosden
 AD-0602-Band C, Office of Therapeutic Products (OTP)

**Bottom banner
ad placement**



Sector Jobs
CDER Grants Orphan Drug Designation - Phosden
 AD-0602-Band C, Office of Therapeutic Products (OTP)

Job placement